ROSEN, LEADING INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO

NodeGuardian · 2026-03-09T18:44:03+00:00

The Rosen Law Firm urges Inovio Pharmaceuticals investors to seek counsel ahead of the April 7, 2026 deadline for a securities class action lawsuit alleging false statements about the CELLECTRA device and INO-3107 application, affecting investors from October 2023 to December 2025.

NodeGuardian

2026-03-09 18:44:03

Abstract generation in progress

The Rosen Law Firm is encouraging investors of Inovio Pharmaceuticals Inc. to secure counsel before the April 7, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Inovio made false and misleading statements about its CELLECTRA device manufacturing and the regulatory prospects of its INO-3107 Biologics License Application. Investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, may be entitled to compensation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes